Flexion Therapeutics

Transformative Medicine... Where It Matters

  • COVID-19 Update
  • Who We Are
    • Core Principles & Values
    • Executive Committee
    • Board of Directors
    • Corporate Social Responsibility
  • Our Product
  • Our Pipeline
    • FX201
    • FX301
  • Our Science
    • Unmet Need in Osteoarthritis
    • Clinical Trials and Associated Publications
  • News
    • Press Releases
  • Investors
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Information
    • Analyst Coverage
    • Contact Us
  • Careers
    • Our Culture
    • Benefits
  • Contact
    • Medical Information Request Form
    • Partnering
    • Patient Expanded Access
    • Report a Compliance Matter
  • COVID-19 Update

Our Science

Portfolio and Capabilities

Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions.

Flexion is committed to the development of a portfolio of local therapeutics for patients in need. In that regard, we are focusing our efforts by building upon the competencies acquired from our research.

Flexion has:

  • Established expertise in the development of formulations that sustain therapeutic effect following local delivery.
  • A presence in the community of Orthopedic and Sports Medicine Surgeons. We look to the development of products that integrate novel pharmacology in the enhancement of the effect and in the improvement of recovery from orthopedic procedures.
  • A strong scientific affiliation with the community of Rheumatologists investigating the underlying disease process of OA, and we maintain an interest in the development of therapeutics that target this disease.
  • Expertise in the development of pain therapies, with a deep understanding of the clinical endpoints representing pain. We look to develop products that provide local analgesic effect in a range of musculoskeletal disorders.
  • A substantial infrastructure including preclinical, CMC, and operational experts to rapidly bring forward new candidates.
  • A keen interest in exploring in-licensing opportunities to expand the Flexion portfolio.
  • Who We Are
    • Core Principles & Values
    • Executive Committee
    • Board of Directors
    • Corporate Social Responsibility
  • Our Product
  • Our Pipeline
    • FX201
    • FX301
  • Our Science
    • Unmet Need in Osteoarthritis
    • Clinical Trials and Associated Publications
  • News
    • Press Releases
  • Investors
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Information
    • Analyst Coverage
    • Contact Us
  • Careers
    • Our Culture
    • Benefits
  • Contact
    • Medical Information Request Form
    • Partnering
    • Patient Expanded Access
    • Report a Compliance Matter
  • COVID-19 Update

© 2021, Flexion Therapeutics Inc.

781.305.7777

Website Design & Development by Graphic Beans

Terms of Use Sitemap Privacy Policy

Connect with us: LinkedIn-whiteTwitter-whiteGlassdoor-white